RT Conference Proceedings
T1 Results of the phase Ib dose escalation study of MEN1611, a PI3K inhibitor, combined with trastuzumab (T) +/- fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC)
A1 Piccart, M.
A1 Ruiz Borrego, M.
A1 Duhoux, F.
A1 Arkenau, H-T.
A1 Doger de Speville, B.
A1 Wildiers, H.
A1 Campone, M.
A1 Tosi, D.
A1 Garcia-Corbacho, J.
A1 Jimenez, B.
A1 Escriva-de Romani, S.
A1 Wardley, A. M.
A1 Tassone, P.
A1 Boni, V.
A1 Jerez, Y.
A1 Aftimos, P. G.
A1 Hennequin, A.
A1 Amair-Pinedo, F.
A1 Pellacani, A. U. E.
A1 Laurent, D. O.
PB Elsevier
SN 0923-7534
YR 2020
FD 2020-09-01
LK https://hdl.handle.net/10668/27097
UL https://hdl.handle.net/10668/27097
LA en
DS RISalud
RD Apr 7, 2025